keyword
MENU ▼
Read by QxMD icon Read
search

Pet psma

keyword
https://www.readbyqxmd.com/read/29688951/prediction-of-normal-organ-absorbed-doses-for-177lu-lu-psma-617-using-44sc-sc-psma-617-pharmacokinetics-in-patients-with-metastatic-castration-resistant-prostate-carcinoma
#1
Ambreen Khawar, Elisabeth Eppard, Jean Phlippe Sinnes, Frank Roesch, Hojjat Ahmadzadehfar, Stefan Kürpig, Michael Meisenheimer, Florian C Gaertner, Markus Essler, Ralph A Bundschuh
In vivo pharmacokinetic analysis of [Sc]Sc-PSMA-617 was used to determine the normal organ-absorbed doses that may result from therapeutic activity of [Lu]Lu-PSMA-617 and to predict the maximum permissible activity of [Lu]Lu-PSMA-617 for patients with metastatic castration-resistant prostate carcinoma. METHODS: Pharmacokinetics of [Sc]Sc-PSMA-617 was evaluated in 5 patients with metastatic castration-resistant prostate carcinoma using dynamic PET/CT, followed by 3 static PET/CT acquisitions and blood sample collection over 19...
April 23, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29688950/68ga-labeled-psma-uptake-in-nonprostatic-malignancies-has-the-time-come-to-remove-ps-from-psma
#2
Dharmender Malik, Rajender Kumar, Bhagwant Rai Mittal, Harmandeep Singh, Anish Bhattacharya, Shrawan Kumar Singh
PET/CT with Ga-labeled prostate-specific membrane antigen (PSMA) is increasingly recognized as the best imaging modality for disease staging and detection of recurrent prostate cancer. Despite its name, PSMA expression has been reported in a number of nonprostatic benign and malignant pathologies. Apparently, angioneogenesis is the mechanism attributed to increased Ga-PSMA uptake at these sites. Here we illustrate the utility of Ga-PSMA in 5 nonprostatic malignancies that could open up new possibilities for diagnostics and theranostic concepts with PSMA labeled radioligands in nonprostate tumor entities...
April 23, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29688944/re-false-positive-uptake-in-bilateral-gynecomastia-on-68ga-psma-pet-ct-scan
#3
Gozde Daglioz Gorur, Turkay Hekimsoy, Serkan Isgoren
No abstract text is available yet for this article.
April 23, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29687208/could-68-ga-psma-pet-ct-become-a-new-tool-in-the-decision-making-strategy-of-prostate-cancer-patients-with-biochemical-recurrence-of-psa-after-radical-prostatectomy-a-preliminary-monocentric-series
#4
Berardino De Bari, Rosario Mazzola, Dario Aiello, Sergio Fersino, Fabiana Gregucci, Pierpaolo Alongi, Maurizio Nicodemo, Stefano Cavalleri, Matteo Salgarello, Filippo Alongi
AIM: To evaluate the impact of gallium68 PSMA-11 (HBED-CC)-PET/CT on decision-making strategy of patients with relapsing prostate cancer (PC) presenting a second biochemical relapse after radical prostatectomy (RP) and salvage RT or salvage androgen deprivation therapy (ADT). MATERIALS AND METHODS: 40 patients were retrospectively analyzed. All of them had received prostatectomy. Thirteen out of 40 were addressed to gallium68 PSMA-11 (HBED-CC)-PET/CT for a biochemical relapse after RP, 14/40 after a salvage RT and 13/40 after salvage or adjuvant ADT...
April 23, 2018: La Radiologia Medica
https://www.readbyqxmd.com/read/29679111/the-impact-of-a-bayesian-penalized-likelihood-reconstruction-algorithm-on-delayed-time-point-ga-68-psma-pet-for-improved-recurrent-prostate-cancer-detection
#5
Tiago Sampaio Vieira, Diogo Borges Faria, Fernando Azevedo Silva, Sérgio Barroso, Graça Fonseca, José Pereira Oliveira
No abstract text is available yet for this article.
April 20, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29678358/impact-of-68-ga-psma-pet-on-the-management-of-patients-with-prostate-cancer-a-systematic-review-and-meta-analysis
#6
REVIEW
Sangwon Han, Sungmin Woo, Yeon Joo Kim, Chong Hyun Suh
CONTEXT: 68 Gallium prostate-specific membrane antigen positron emission tomography (68 Ga-PSMA PET) is an emerging imaging modality for assessment of prostate cancer. Recent studies show promising results regarding its ability to detect recurrent or metastatic prostate cancer superior to that of conventional imaging modalities. However, the impact of 68 Ga-PSMA PET on management of patients with prostate cancer has not been well established. OBJECTIVE: To perform a systematic review and meta-analysis to evaluate the impact of 68 Ga-PSMA PET on management of patients with prostate cancer...
April 17, 2018: European Urology
https://www.readbyqxmd.com/read/29676909/-18-f-positron-emitting-trimethine-cyanine-fluorescent-contrast-for-image-guided-prostate-cancer-management
#7
Harikrishna Kommidi, Hua Guo, Fuad Nurili, Yogindra Vedvyas, Moonsoo M Jin, Timothy D McClure, Behfar Ehdaie, Haluk B Sayman, Oguz Akin, Omer Aras, Richard Ting
[18/19 F]-4, an anionic GCPII/PSMA inhibitor for image-guided intervention in prostate cancer, is described. [19 F]-4 is radiolabeled with a radiochemical yield that is ≥27% and a molar activity of 190 ± 50 mCi/μmol in a <1 h, one-step, aqueous isotopic exchange reaction. [19 F]-4 allows PSMA expression to be imaged by fluorescence (FL) and [18 F]-PET. PC3-PIP (PSMA-positive, EC50 = 6.74 ± 1.33 nM) cancers are specifically delineated in mice that bear 3 million (18 mg) PC3-PIP and PC3 (control, PSMA-negative) cells...
April 20, 2018: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29664244/the-role-of-68ga-psma-pet-ct-scan-in-biochemical-recurrence-after-primary-treatment-for-prostate-cancer-a-systematic-review-of-literature
#8
Ahmed Eissa, Ahmed El Sherbiny, Rafael F Coelho, Jens Rassweiler, John W Davis, Francesco Porpiglia, Vipul R Patel, Napoleone Prandini, Salvatore Micali, Maria C Sighinolfi, Stefano Puliatti, Bernardo Rocco, Giampaolo Bianchi
INTRODUCTION: Recurrence after primary treatment of prostate cancer is one of the major challenges facing urologists. Biochemical recurrence is not rare and occurs in up to one third of the patients undergoing radical prostatectomy. Management of biochemical recurrence is tailored according to the site and the burden of recurrence. Therefore, developing an imaging technique to early detect recurrent lesions represents an urgent need. Positron emission tomography (PET) of 68Ga-labelled prostate-specific membrane antigen (68Ga-PSMA) is an emerging imaging modality that seems to be a promising tool with capability to localize recurrent prostate cancer...
April 17, 2018: Minerva Urologica e Nefrologica, the Italian Journal of Urology and Nephrology
https://www.readbyqxmd.com/read/29664103/microfluidic-68-ga-labeling-a-proof-of-principle-study
#9
Sarah Pfaff, Cecile Philippe, Verena Pichler, Marcus Hacker, Markus Mitterhauser, Wolfgang Wadsak
Positron emission tomography (PET) as a tool for molecular imaging of cancer has gained huge interest in the last few years. Gallium-68 is a popular PET nuclide due to its favorable characteristics, like advantageous half-life (68 min) and independency of a cyclotron on-site for its production. Accordingly, several 68Ga-complexes for cancer imaging via PET have been made available during the last few years. In this work, 68Ga-labeled compounds were synthesized applying a commercially available microfluidic device for the first time...
April 17, 2018: Dalton Transactions: An International Journal of Inorganic Chemistry
https://www.readbyqxmd.com/read/29663686/-68-ga-psma-pet-ct-staging-prior-to-definitive-radiation-treatment-for-prostate-cancer
#10
George Hruby, Thomas Eade, Louise Emmett, Bao Ho, Ed Hsiao, Geoff Schembri, Linxin Guo, Carolyn Kwong, Julia Hunter, Keelan Byrne, Andrew Kneebone
AIM: To explore the utility of prostate specific membrane antigen (PSMA)-positron emission tomography (PET)/computed tomography (CT) in addition to conventional imaging prior to definitive external beam radiation treatment (EBRT) for prostate cancer. METHODS: All men undergoing PSMA-PET/CT prior to definitive EBRT for intermediate and high-risk prostate cancer were included in our ethics approved prospective database. For each patient, clinical and pathological results, in addition to scan results including site of PSMA positive disease and number of lesions, were recorded...
April 16, 2018: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29659395/loss-of-psma-expression-in-non-neuroendocrine-dedifferentiated-acinar-prostate-cancer
#11
Peter Bronsert, Kathrin Reichel, Juri Ruf
The introduction of tracers targeting the prostate-specific membrane antigen (PSMA) has revolutionized PET imaging of acinar prostate adenocarcinoma. In general, an increasing PSMA expression is assumed with increasing dedifferentiation. Whereas loss of PSMA expression has been reported in case of neuroendocrine dedifferentiation, we present a patient with acinar prostate adenocarcinoma with a loss of PSMA expression after chemotherapy on PET/CT and in histological and immunohistochemical analyses. All tissue samples indicated the retention of acinar features but no expression of neuroendocrine markers (NSE, synaptophysin, chromogranin, and CD56), corresponding to nonelevated serum NSE...
April 13, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29659383/prostate-specific-membrane-antigen-negative-metastases-a-potential-pitfall-in-prostate-specific-membrane-antigen-pet
#12
Benjamin Noto, Katharina Auf der Springe, Sebastian Huss, Thomas Allkemper, Lars Stegger
Ga-PSMA-11 PET/CT was performed in a 74-year-old man because of biochemical recurrence of prostate cancer following radiation therapy of the prostate gland 24 months earlier. Besides focal nuclide accumulation in the prostate gland suggestive of local recurrence, PET scan revealed no further pathologic uptake. However, CT showed multiple pulmonic nodules suggestive of metastases. Thoracotomy and pathologic examination revealed the nodules to be prostate cancer metastasis. Furthermore, immunohistochemical staining with PSMA antibodies demonstrated a virtual lack of PSMA expression...
April 13, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29655611/development-of-a-ga-68-labeled-pet-tracer-with-short-linker-for-prostate-specific-membrane-antigen-psma-targeting
#13
Sung-Hyun Moon, Mee Kyung Hong, Young Ju Kim, Yun-Sang Lee, Dong Soo Lee, June-Key Chung, Jae Min Jeong
Glu-Urea-Lys (GUL) derivatives have been reported as prostate-specific membrane antigen (PSMA) agent. We developed derivatives of GUL conjugated with NOTA or DOTA via a thiourea linker and tested their feasibility as PSMA imaging agents after labeling with 68 Ga. NOTA-GUL and DOTA-GUL were synthesized and labeled with 68 Ga using generator-eluted 68 GaCl3 in 0.1 M HCl in the presence of 1 M NaOAc at pH 5.5. The stabilities of 68 Ga-labeled compounds in human serum were tested at 37.5 °C. A competitive binding assay was performed using the PSMA-positive prostate cancer cell line 22Rv1 and [125 I]MIP-1072 (PSMA-specific binding agent) as a tracer...
April 5, 2018: Bioorganic & Medicinal Chemistry
https://www.readbyqxmd.com/read/29650029/the-dose-distribution-in-dominant-intraprostatic-tumour-lesions-defined-by-multiparametric-mri-and-psma-pet-ct-correlates-with-the-outcome-in-patients-treated-with-primary-radiation-therapy-for-prostate-cancer
#14
Constantinos Zamboglou, Christina Marie Klein, Benedikt Thomann, Thomas Franz Fassbender, Hans C Rischke, Simon Kirste, Karl Henne, Natalja Volegova-Neher, Michael Bock, Mathias Langer, Philipp T Meyer, Dimos Baltas, Anca L Grosu
No abstract text is available yet for this article.
April 12, 2018: Radiation Oncology
https://www.readbyqxmd.com/read/29643670/role-of-early-dynamic-positron-emission-tomography-computed-tomography-with-68ga-prostate-specific-membrane-antigen-hbed-cc-in-patients-with-adenocarcinoma-prostate-initial-results
#15
Gazala Perveen, Geetanjali Arora, Nishikant Avinash Damle, Meghana Prabhu, Saurabh Arora, Madhavi Tripathi, Chandrasekhar Bal, Praveen Kumar, Rajeev Kumar, Prabhjot Singh
Rationale: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) is widely used for imaging of prostate cancer (PC) nowadays. However, appearance of bladder activity many a times hampers lesion detection vis-a-vis primary as well as regional nodes. We aimed to assess if early dynamic PET/CT can be a potential solution to this issue. Methodology: A total of 15 biopsy-proven PC patients who were referred to our department for 68 Ga-PSMA PET/CT for staging/restaging were prospectively studied...
April 2018: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/29629912/technical-pitfall-in-68ga-prostate-specific-membrane-antigen-imaging-altered-biodistribution-caused-by-free-68ga-citrate-due-to-radiolysis-showing-increased-vascular-activity
#16
Nir Hod, Reut Anconina, Daniel Levin, Dina Ezroh Kazap, Sophie Lantsberg
As with any new molecular imaging modality, accurate characterization of abnormalities on Ga-PSMA PET/CT imaging can be accomplished only if one is aware of the normal distribution pattern, physiological variants, and potential sources of false imaging findings. Altered biodistribution can have a significant impact on scan interpretation. Presented here is a rare case in which radiopharmaceutical radiolysis occurred causing excessive free Ga-citrate showing as an increased vascular activity. As Ga-PSMA PET/CT imaging is a relatively new imaging technique, it is important to be aware of such a potential technical pitfall in clinical practice in order to prevent scan misinterpretation...
April 6, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29626569/a-voice-from-the-past-re-discovering-the-virchow-node-with-psma-targeted-18-f-dcfpyl-pet-imaging
#17
Rudolf A Werner, Christian Andree, Mehrbod S Javadi, Constantin Lapa, Andreas K Buck, Takahiro Higuchi, Martin G Pomper, Michael A Gorin, Steven P Rowe, Kenneth J Pienta
No abstract text is available yet for this article.
April 4, 2018: Urology
https://www.readbyqxmd.com/read/29625755/-99m-technetium-based-prostate-specific-membrane-antigen-radioguided-surgery-in-recurrent-prostate-cancer
#18
Tobias Maurer, Stephanie Robu, Margret Schottelius, Kristina Schwamborn, Isabel Rauscher, Nynke S van den Berg, Fijs W B van Leeuwen, Bernhard Haller, Thomas Horn, Matthias M Heck, Jürgen E Gschwend, Markus Schwaiger, Hans-Jürgen Wester, Matthias Eiber
BACKGROUND: Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) can visualize metastatic lesions in recurrent prostate cancer (PC). However, reliable identification of small and/or atypically localized lesions during salvage surgery procedures is challenging. OBJECTIVE: To describe the technique, feasibility, and short-term outcomes of99m Technetium (99m Tc)-based PSMA-radioguided surgery (99m Tc-PSMA-RGS) for removal of recurrent PC lesions...
April 3, 2018: European Urology
https://www.readbyqxmd.com/read/29619657/hallmarks-in-prostate-cancer-imaging-with-ga68-psma-11-pet-ct-with-reference-to-detection-limits-and-quantitative-properties
#19
Alejandro Sanchez-Crespo, Emma Jussing, Ann-Charlotte Björklund, Katja Pokrovskaja Tamm
BACKGROUND: Gallium-68-labeled prostate-specific antigen positron emission tomography/computed tomography imaging (Ga68-PSMA-11-PET/CT) has emerged as a potential gold standard for prostate cancer (PCa) diagnosis. However, the imaging limitations of this technique at the early state of PCa recurrence/metastatic spread are still not well characterized. The aim of this study was to determine the quantitative properties and the fundamental imaging limits of Ga68-PSMA-11-PET/CT in localizing small PCa cell deposits...
April 4, 2018: EJNMMI Research
https://www.readbyqxmd.com/read/29616296/psma-pet-guided-hook-wire-localization-of-nodal-metastases-in-prostate-cancer-a-targeted-approach
#20
REVIEW
Emma Clarebrough, Catriona Duncan, Daniel Christidis, Alain Lavoipierre, Nathan Lawrentschuk
Prostate Specific Membrane Antigen Positron Emission Tomography/Computed Tomography (PSMA-PET/CT) has increased the sensitivity and specificity of imaging to identify metastatic prostate cancer in the group of patients with early biochemical recurrence when compared to conventional imaging. In patients who develop biochemical recurrence of prostate cancer following surgical resection, salvage lymph node dissection may reduce prostate specific antigen (PSA) levels and delay the time for commencement of systemic therapies...
April 3, 2018: World Journal of Urology
keyword
keyword
110902
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"